October, 2025, PRIMABS recent article in the International Journal of Molecular Sciences (doi:10.3390/ijms26209859) describes Eutropics’ PRIMAB conformation‑specific antibody platform, which directly measures BCL‑2 family protein–protein interactions to predict BH3‑mimetic response. Independent groups are now citing this work in the context of BH3 profiling and functional precision oncology, highlighting PRIMABS’ potential as a clinically deployable companion diagnostic for apoptosis‑targeted therapies.
